Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study

Ramalingam, Suresh S; Carlisle, Jennifer W

doi:10.6084/m9.figshare.26928090.v1

Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study

journal contribution

posted on 2024-09-03, 14:00 authored by Suresh S Ramalingam, Jennifer W Carlisle

Drs. Ramalingam and Carlisle discuss the incidence and pathophysiology of BRAF V600E-mutant metastatic non-small cell lung cancer and current treatment options. The podcast provides an overview of the data from the recent Pfizer-sponsored phase 2 PHAROS (NCT03915951) study, which were the basis for the recent US Food and Drug Administration approval of encorafenib plus binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer.

A PDF version of this infographic is available as supplemental material.

Funding

S Ramalingam reports a consulting or advisory role with GlaxoSmithKline; research funding to institution from AbbVie, Bristol Myers Squibb, Pfizer, Merck, AstraZeneca/MedImmune, Vertex, Takeda, EMD Serono, Genmab, Advaxis and Amgen; and travel and accommodation expenses from AstraZeneca and AbbVie.

Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study

Funding

S Ramalingam reports a consulting or advisory role with GlaxoSmithKline; research funding to institution from AbbVie, Bristol Myers Squibb, Pfizer, Merck, AstraZeneca/MedImmune, Vertex, Takeda, EMD Serono, Genmab, Advaxis and Amgen; and travel and accommodation expenses from AstraZeneca and AbbVie.

History

Usage metrics

Categories

Keywords

Licence

Exports